与安慰剂组的14%相比,服用吡格列酮组肝脏的胰岛素敏感型改善了48%。
Insulin sensitivity in the liver improved by 48 percent in the pioglitazone group, compared to 14 percent in the placebo group.
吡格列酮联用磺脲类、胰岛素或者二甲双胍用于8项试验(8501个病人)。
Pioglitazone was tested in combination with a sulfonylurea, insulin, or metformin in 8 trials (8501 patients).
目的观察罗格列酮的胰岛素增敏作用和胰岛素抵抗改善作用。
AIM To observe the insulin sensitizing effect and insulin resistance ameliorating effect of rosiglitazone.
应用推荐